AgingResearch.NewsJoin free

Stereotactic body radiation therapy

Stereotactic body radiation therapy has been studied in 3 papers since 2026: 3 observational studies in people; 3 in the past year. The newest story, Nov 8, 2026: “Broadly similar quality of life by age in localized pancreatic cancer”.

Exposure

3 papers study it1 findingUpdated

See all 3 papers on stereotactic body radiation therapy

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“17.6% (n = 58) experienced MACE, with a risk-adjusted cumulative incidence at 2 years of 13.0%.”
Cardiac risk, outcomes, and management among older adults with stage I-II non-small cell lung cancer undergoing stereotactic body radiation therapyJournal of geriatric oncology2026doi:10.1016/j.jgo.2026.102943
Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: National Cancer Institute and 1 more
  • 1 of 1 finding with company ties
  • Humans3

What is stereotactic body radiation therapy linked with?

1

Studies link stereotactic body radiation therapy with major adverse cardiac events.

Major adverse cardiac events

upin humans1

1 study

  1. Stereotactic body radiation therapy is associated with major adverse cardiac events in humans (early-stage NSCLC undergoing SBRT) (17.6% (n = 58) experienced MACE, 2-year cumulative incidence 13.0%).

    “17.6% (n = 58) experienced MACE, with a risk-adjusted cumulative incidence at 2 years of 13.0%.”

    Humansearly-stage NSCLC undergoing SBRTmedian follow-up of 21.3 monthsn = 330

    Cardiac risk, outcomes, and management among older adults with stage I-II non-small cell lung cancer undergoing stereotactic body radiation therapy

    Journal of geriatric oncology

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 1Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 03 papers in 12 months
European Journal of Cancer

Broadly similar quality of life by age in localized pancreatic cancer

In a nationwide cohort of 5,217 patients, age was not independently linked to overall survival after treatment for localized pancreatic cancer.In a nationwide cohort of 5,217 patients, age was not independently linked to overall survival after treatment for localized pancreatic cancer.

Cohort · 5,217 peoplePancreatic cancer
Paper

Related